On June the IUPHAR Section of Immunopharmacology and the Cuban
as whooping cough, this has been one of the most persistent and extended infectious diseases, with more than 200 000 deaths per year and 20 million cases worldwide, according to the World Health Organization (WHO). This situation exists today in spite of high vaccine coverage A irst generation of vaccines consisting of suspensions of Bordetella pertussis cells has been used since the s with high levels of ef icacy However concerns about several drawbacks such as local reactions, fever and even some not substantiated neurological disorders has driven the development and application of vaccines based on isolated and puri ied antigens as opposed to whole cells This second generation of acellular vaccines (aP) containing either three or ive puri ied antigens adsorbed to alum and co formulated with other antigens, although less reactogenic, has not conferred the same level of protective immunity against B pertussis as the original whole cell pertussis wP vaccines In fact its introduction in the 1980s has been linked to the resurgence of whooping cough in developed countries, where had changed from wP to aP vaccines. One explanation of the failure of these aP vaccines is attributed to the induction of IgG antibodies and T helper Th cells whereas the wP vaccines generate a Th Th response which is thought to be important for protection against B pertussis. One solution to the ongoing problem might be a return to wP, but this is generally viewed as unfeasible in countries where aP vaccines are established. Therefore, a third generation of vaccines and new strategies regarding vaccination schedules and policies are in progress [3] .
In this context the session on pertussis vaccines started with a presentation from Dr Waldely O Dias Butantan Institute Brazil), who described the development of an improved wP vaccine, designated as Plow, with low endotoxicity, using a simpli ied and not expensive methodology which also produced monophosphoryl lipid A as a by product to be used as an adjuvant This new wP vaccine with low lipo oligosaccharide (LOS) content, due to a chemical extraction of LOS from the outer membrane, when combined with diphtheria and tetanus antigens (DTPlow) was shown to be as potent as the current pertussis whole cell combined vaccine (DTP vaccine) but less reactogenic. The LOS extraction did not affect the integrity of the product and, more importantly, did not impact on the potency, immunogenicity and or stability of DTPlow Thus this new approach for wP vaccines could be a signi icant improvement and a promising and affordable alternative to currently available pertussis vaccines for developing countries [4] .
Dr Arno van der Ark Netherlands Institute for Translational Vaccinology Intravacc the Netherlands discussed the value of product characterization and immunoproteomic pro iling in the search of improved pertussis vaccines, based mainly on outer membrane vesicles OMV In his presentation Dr van der Ark showed the results of the comparative characterization of wP and OMV vaccines using microarrays for gene expression and enzyme linked immunoassays ELISA to evaluate antigen content as well as immunopro iling by liquid chromatography mass spectroscopy LC MS and dimensional D electrophoresis blotting as well as immunogenicity in mice. Both types of vaccine raised strong antibody responses, but large quantitative and qualitative differences were measured. The highest antibody levels were obtained by OMV The wP vaccine induced IgG a IgG b IgG levels which were signi icantly lower compared to OMV The majority of OMV induced antibodies were directed against Vag BrkA and lipopolysaccharide LPS whereas wP induced antibodies were mainly directed against GroEL FHA and Vag The higher IgG a IgG b and IgG antibody responses induced by OMV indicate more functional antibodies were induced, although this needs to be con irmed in functional assays A presentation by Dr Diógenes Quintana Center of Genetic Engineering and Biotechnology CIGB Cuba introduced his work on the design of new recombinant molecules comprising the complete sequences regions of two different types of pertactin PRN PRN molecules bear two variable R regions from Prn and Prn The genes of Prn Prn and six variants of PRN were cloned in Escherichia coli and PRN proteins were over expressed at of total protein concentrations using the pET a BL Codonplus RP expression system The proteins were puri ied and after refolding the PRNs were recognized by anti PRN monoclonal antibodies binding protective conformational and linear epitopes regions The PRN proteins were highly immunogenic in BALB c mice with the induction of IgG a and IgG b subtypes In particular two PRNs PRN lc PRN induced highly signi icant p anti Prn antibody levels The PRN lc and PRN molecules exhibited an enhanced immunological pro ile in BALB c mice in terms of the level of whole anti Prn IgG antibodies with respect to natural Prn controls.
Dr Coenraad Hendriksen Intravacc the Netherlands outlined the consistency approach, the new paradigm in lot release testing of established vaccines. This approach starts from the idea that subsequent lots of vaccine produced can be compared with a clinical historical lot which is thoroughly tested and has a well de ined pro ile
The consistency approach has come into being by improvements in production and control: optimized production processes a tight protocol for in process testing using innovative physico and immunochemical techniques in vitro cell culture techniques and bioinformatics) and a state of the art quality monitoring system Good Manufacture Practice GMP Quality Assurance QA Consistency testing may lead to a signi icant reduction in animal use since a narrow set of animal tests performed on each inal lot sometimes with questionable relevance, may be replaced by a battery of meaningful physicochemical immunochemical and in vitro functional tests with enhanced capacity to measure equivalence with batches of proven safety and ef icacy Dr Hendriksen also showed some proof of concept data of the consistency testing for pertussis, rabies and diphtheria vaccines [8] .
Finally Dr Mario Landys Chovel Finlay Vaccine Institute
Cuba) discussed the development of a pertussis serological potency test (PSPT) and its correlation with protection. The Mouse Protection Test MPT still remains the gold standard for Pertussis Potency in vaccines, but it has been broadly criticized in terms of variability scienti ic relevance ethics and high cost As PSPT correlates well with MPT it appears to be a very promising alternative to the challenge method. However, its biological relevance, namely the mechanisms related to the role of the antibodies detected with protection, are rather unclear. Dr. Chovel showed that whole antibody titres instead of speci ic antibody titres correlated with MPT activities Likewise IgG a and IgG b subclasses were generated during the PSPT, suggesting a role for antibodies in inducing phagocytosis by phagocytes like neutrophils and macrophages. The results derived from an in vitro opsonophagocytosis model correlated well with the PSPT and the MPT con irming this pathway as signi icant in explaining the role of the antibodies in the protection induced by wP. Thus, this alternative method could provide not only a potential replacement of MPT but also a valuable tool for estimating the biological relevance of new pertussis vaccines [9].
Pneumoccocal Vaccines. Learned Lessons
The main goals of the Pneumococcal Vaccine Symposium, were to provide an update on scienti ic information about Pneumococcal Conjugate Vaccines (PCV) and to share with international experts the strategy for the development of the Cuban pneumococcal conjugate vaccine. The introduction of Prevnar in the USA in was an important success in the ight against pneumococcal diseases due to its high ef icacy in preventing diseases and death caused by pneumococci. Also, a reduction of child mortality was reported in children below years and a substantial decrease in Invasive Pneumococcal Disease IPD) in other non immunized age groups was documented [11, 12] . For many years in the last decade, the vaccine was only available for developed countries Nowadays the licensed PCV Prevnar and Syn lorix are available in many countries of the world, even in very poor countries thanks to the efforts of GAVI with more than countries now having rolled out the vaccine [13] . On the other hand, several middle income countries are non eligible for GAVI therefore they are not able to access them because of the high price of these vaccines.
WHO recommends the inclusion of pneumococcal vaccines in childhood immunization programs worldwide, especially in countries with under ive mortality of greater than per 1000 live births. Schedules of three primary doses (3p+0) or, as an alternative, two primary doses plus a booster (2p+1) are recommended, although the 3+1 is still used in several developed countries Primary vaccination can be initiated as early as at weeks of age WHO also recommends catch up vaccination during pneumococcal vaccine introduction to accelerate herd protection and PCV impact on disease and carriage [14] . The differences between the 2p+1 and 3p+0 schedules are subtle, especially in countries with a mature immunization program in which coverage is high and indirect effects help enhance protection provided directly by a vaccine schedule Strong evidence was provided during the session about the ef icacy and the impact of PCV established through multiple clinical trials PCV demonstrated ef icacy of against invasive pneumococcal disease caused by serotypes contained in the vaccine [11] . PCV10 has been effective against invasive pneumococcal diseases in Brazil with CI against vaccine serotypes and against vaccine related serotypes PCV has recorded data on ef icacy initially inferred before licensure from an aggregate correlate of protection, established for PCV and later a post licensure assessment of serotype speci ic vaccine effectiveness and immunogenicity in England Wales and Northern Ireland was reported with vaccine effectiveness of for the PCV serotypes and for the six additional serotypes included in PCV Other non licensed vaccines were also effective preventing pneumonia and mortality in different regions [18, 19] .
The need of alternative PCV dosing schedules was also discussed during the symposium, based on the need for some countries to reduce cost of their immunization programs. Thanks to the work of GAVI and Vaccine Alliance partners most of the world's poorest children are now receiving PCV, but the sustainability of this vaccination could be compromised when these countries graduate from GAVI and one of the strategies is the reduction of the number of PCV doses Rückinger et al [20] have published a metanalysis estimating that about fewer children achieve antibody levels of g ml after two primary immunizations compared to three primary immunizations for most of serotypes included in one of the licensed pneumococcal conjugate vaccines. This difference in proportion was higher for serotypes B and F where and fewer children achieved protective antibody levels These indings support the fact that the majority of children were protected by two primary immunizations with pneumococcal conjugate vaccines in the irst year of life Then following the control of pneumococcal vaccine type disease and colonization through vaccination could be decided by some countries by changing the PCV schedule to single priming and a booster dose would be suf icient to sustain that control at reduced costs This option should be evaluated and clinical evidence should be generated for supporting this approach.
Professor David Goldblatt provided an update on the next generation of pneumococcal vaccines. Some PCV are under development by manufactures such as Merck a valent vaccine Serum Staten Institute of India a valent vaccine Finlay Vaccine Institute Cuba a valent vaccine among some others It may be dif icult for manufacturers not belonging to the big pharmaceutical companies to enter the PCV market, but many countries will be graduating from GAVI eligibility over the next years so there is a market for cheaper vaccines that can be supplied to these countries and which will cover the key serotypes prevalent in those countries Undoubtedly the effectiveness of PCVs has led to the development of higher valence vaccines, to combat in part, serotype replacement, but it is unclear how many serotypes can be added to a single conjugate vaccine and serious physico chemical and immunological challenges are expected Nevertheless as the Target Product Pro ile has recognized the combination of of them could be enough to cover more than of the invasive disease isolates in the target region and considerable public health impact may be expected [23] .
Protein based vaccines offer the promise of serotype independent immunity, but not even one has been licensed until now, mainly because the regulatory pathway for their licensure remains unde ined New vaccines containing highly conserved Streptococcus pneumoniae proteins such as pneumolysin toxoid dPly and histidine triad protein D PhtD are being developed to provide broader protection against pneumococcal disease, which are well tolerated and immunogenic when administered to healthy adults [24] . Several approaches have been followed for protein based vaccines One strategy has been the combination of proteins with conjugates The combination of PCV Syn lorix with PhtD and dPly were immunogenic either for polysaccharide and protein antigens, and the investigational vaccine formulations were well tolerated when administered to toddlers as a dose primary vaccination followed by a booster dose PCV has been evaluated in combination with two pneumococcal proteins in Navajo Indians with subjects with PCV and 900 with PCV13 more PhtD and dPly proteins. This clinical trial has as primary endpoint clinical OAM and the secondary endpoint is ef icacy against nasopharyngeal carriage of non PCV serotypes Goldblatt personal communication Another strategy has been to use pneumococcal proteins as a carrier for capsular polysaccharide. A clinical trial was conducted in healthy elderly adults to examine the safety, reactogenicity, and immunogenicity of six different investigational pneumococcal vaccine formulations containing AS02V or alum adjuvant with PhtD and dPly proteins either conjugated to pneumococcal polysaccharide in an valent PCV PCV or as free proteins Nevertheless the regulatory pathway for the licensure of protein based vaccines is unclear and correlates of protection need to be found.
The inal session of the symposium was dedicated to
the discussion and critical review of the Cuban strategy for the development of a heptavalent pneumococcal conjugate vaccine PCV TT using tetanus toxoid TT as a carrier and the implementation of a clinical research strategy and impact evaluation of this new vaccine. This candidate vaccine has been developed by the same research team that developed the irst human vaccine using a fully synthetic polysaccharide antigen:
Quimi Hib
The PCV TT vaccine was designed to be used in Cuba and other countries with the good ratio of cost effectiveness In contrast to the current PCV and PCV strategies the number of serotypes was kept at seven, but with a more rational selection than the original PCV ive serotypes B C F and F are the same compared to the original Prevnar formulation but serotypes and were additionally included instead of increasing the number of serotypes, and the corresponding 4 and 9V serotypes were not included because they are found in lower prevalence than and worldwide Additionally an important cross protection is expected for serotypes A and A The Cuban strategy keeps the number of serotypes at seven, as it is considered the best number to get wide coverage and to enable faster vaccine development. The candidate vaccine contains as active ingredients the CPS of serotypes B C F and F coupled by reductive amination to TT, adsorbed on aluminum phosphate as the adjuvant. The preclinical research stages of this vaccine have demonstrated immunogenicity and safety in animal models, the technology has been scaled up and several batches have been produced for clinical trials.
The clinical research strategy and impact evaluation of this vaccine is based on the necessity to introduce pneumococcal vaccines into the Cuban National vaccination program to impact on the burden of IPD and to provide scienti ic evidence to support the use and commercialization of this vaccine in the PCV13 era. The clinical evaluation strategy and impact evaluation for this vaccine is summarized in Figure 1 .
The PCV TT vaccine was initially evaluated in healthy
young adults during a controlled, randomized and double blind Phase I clinical trial using polysaccharide vaccine Pneumo Sano i Pasteur as a control This clinical trial demonstrated that the candidate vaccine PCV TT was safe when used in healthy adults and immunological results showed that after a single dose, the concentration of antibodies increased signi icantly in both groups with respect to pre vaccination Clinical trials in children and infants was the next stage in clinical evaluation of this vaccine in order to obtain a license for these target populations. Firstly, we evaluated the vaccine in infants of months old with a schedule at and months and the results showed low reactogenicity (unpublished data).
During a Phase I II clinical trial have been doing in infants month old
The PCV TT vaccine will be licensed in Cuba irstly for children and then for infants, with a window of a year or two. This time will give us the unique possibility to study the impact of PCV vaccination on infants and other unvaccinated populations [30, 31] . The current PCVs were initially introduced in infants sometimes accomplished by a catch up for children
The Cuban strategy will introduce vaccination of children between years old as a short term mass vaccination campaign with high coverage contributing to provide scienti ic evidence about the impact on reduction of nosocomial pneumonia colonization rates and the incidence of IPD in vaccinated and unvaccinated subjects, including infants. Excellent results were found in a mass campaign with MenAfrivac in Mali Burkina Faso and some other African countries based on similar strategy [30,31].
Enteric Vaccines. The promise of the future
The Enteric Vaccines (EV) Symposium received prominent experts and members of international programs involved in the development of vaccines against enteric pathogens.
Food waterborne diseases are a worldwide problem and a major cause of childhood deaths in developing countries [32] . Certainly, the best strategy of control will be the improvement of water supplies and sanitation; however, these measures may not be achievable in the near future in most developing countries. For that reason vaccination has become a short to mid term strategy 
Salmonella Typhi and Paratyphi A
Caused mainly by Salmonella enterica serovar Typhi and serovar Paratyphi A, enteric fever is still an important public health problem in many developing countries [34] . Even though live attenuated and Vi capsular polysaccharide vaccines have been available for more than 30 years ago, almost no country has implemented vaccination against typhoid at country level. Part of the reason for their lack of use in at risk populations is their short term protection and poor immunogenicity in young children
At present no vaccines speci ic to S Paratyphi A are available In this regard a new generation of improved vaccine candidates has been emerging; all focused on the induction of a long lasting immune response in all age groups Among them anti typhoid conjugate vaccines is the most advanced strategy with three vaccines already licensed for in country use in India and China Similarly efforts have been made in the development of candidates against Paratyphi A, in order to obtain a bivalent vaccine versus both pathogens
Dr. Sushant Sahastrabuddhe, Program Leader of Enteric and Diarrheal Diseases at International Vaccine Institute IVI Korea), introduced the session with a presentation about the burden of typhoid and paratyphoid fever and the strategies for control Dr M Imran Khan former Director of Coalition against Typhoid discussed how even though vaccines against typhoid have been available for several years, the absence of global inancing support has resulted in minimal national uptake However GAVI commitment to support a typhoid conjugate vaccine is encouraging Dr Khalid Ali Syed Associate Research Scientist from IVI talked about the typhoid conjugate vaccine candidate developed at IVI its technology transfer to four manufacturers and the clinical development plan for use in children less than 2 years of age. He also discussed the need of a paratyphoid vaccine based on the signi icant disease burden the increasing antimicrobial resistance and the non existence of vaccines against this disease. On the other hand, Sonsire Fernández Project Manager at Finlay Vaccine Institute showed the impact of sanitation measures and typhoid vaccination with 
Tuberculosis Vaccine
The Tuberculosis (TB) Vaccines Symposium was focused on the presentation of important research on global TB epidemics and the efforts to develop new vaccines to prevent TB. The congress was honored to host a wide representation of International Foundations Institutes and Universities which carry out research and or inance studies related to TB TB continues to be a central point of attention for many research groups worldwide Even though the Bacille Calmette Guerin BCG vaccine has been administered to thousands of people since 1921, it does not confer adequate protection against pulmonary infection in adults as BCG has only de initively been shown to protect infants and young children from severe, often fatal complications of Mycobacterium tuberculosis Mtb infection
Efforts to obtain a new vaccine that is more robust and ef icient in protecting against Mtb infection than BCG particularly in adolescents and adults as these older age groups are the primary global source of Mtb transmission represents a global health priority. At present, some vaccine candidates are in different clinical phase evaluation Table   1 ). dose of this mutant, showed higher survival rates and less tissue damage than animals infected with the parental strain. Although animals infected with the sigE mutant had low bacillary loads, their lungs showed signi icantly higher production of the protective factors interferon gamma IFN tumor necrosis factor alpha TNF inducible nitric oxide synthase iNOS and beta defensins than those animals infected with the parental or complemented mutant strain Moreover they demonstrated that the sigE mutant, when inoculated subcutaneously, was more attenuated than BCG in immunode icient nude mice and when used as a subcutaneous vaccine, induced a higher level of protection than did BCG after challenge with both H Rv and a highly virulent strain of M tuberculosis Beijing code In order to get a more attenuated vaccine strain they produced a second mutation in the gene fadD that contributed to the production of the virulence factor phthiocerol dimycocerosates DIM producing the double sigE fadD mutant unpublished results Using the same BALB c mice model of progressive TB they showed that the attenuation in fadD single mutant induced less tissue damage than the parental strain. When used as a subcutaneous vaccine, days before intratracheal challenge with a hypervirulent strain of M tuberculosis Beijing code this mutant induced a higher level of protection than did BCG These indings suggested that this double mutant is a very promising strain for the development of a new vaccine against TB.
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Dr Iliana Valdes Tropical Medicine Institute Pedro Kourí
Cuba, described her experiences using M habana as a vaccine candidate against TB It is considered that the protection conferred This symposium represented a unique opportunity to interchange experiences, results, alternatives and strategies relevant to the evaluation of new TB vaccine candidates designed to address the disadvantages of BCG vaccination and to develop TB vaccines for use in adolescents and adults. Additionally, the congress provided an important opportunity to establish contacts join efforts and work together to ight TB.
Vaccines against meningococcal disease; status and perspectives
The Meningoccocal Vaccine Symposium received prestigious researchers from scienti ic and health institutions universities and pharma. The discussion was focused on the current situation of meningococcal vaccines, being the multivalent conjugated polysaccharide vaccines and the recently licensed antimeningococcal serogroup B vaccines. From the early capsular polysaccharide vaccines developed in the late s there has been a gradual improvement in vaccines that have the bacterial polysaccharide (PS) capsule as the protective principle irst as puri ied PS vaccines against one serogroup then as combinations for protection against an increased number of serogroups at the same time More recently the development of protein PS conjugate vaccines and inally the quadrivalent conjugate formulations, against meningococcal serogroups A C Y and W have become some of the most important vaccine strategies ever implemented against these pathogens Important milestones and time points are listed in Figure 2 . The public health impact of the various meningococcal vaccines has been great Dr Ray Borrow Public Health England UK referred to the evolving strategies for meningococcal conjugate vaccination, the importance of immunization schedules and concomitance studies to optimize the induction of immunological memory, protection and protective herd immunity against meningococcus.
The current R D situation of a pentavalent and thermostable vaccine against serogroups ACWY and X was presented by Dr Marc LaForce Serum Institute of India . Dr. LaForce also mentioned the impact of MenAfricVac immunization campaigns in some African countries. This conjugated vaccine against N meningitidis serogroup A has become an affordable solution for developing countries of Africa against epidemics caused by this Nevertheless for more than four decades there has been a challenging search for a vaccine against MenB disease Early on during the development of meningococcal vaccines, it was noticed that the MenB capsule was poorly immunogenic in humans due to molecular mimicry with glycoproteins found in human tissue (especially abundant in the fetal brain). Efforts to break immunological tolerance raised concerns regarding potential autoimmunity reactions and tissue damage in vaccinees in general and pregnant women in particular. Thus, vaccine development Also the protective immune response was directed mainly against the sero subtype de ining epitopes on PorA a highly variable porine protein This phenomenon was most signi icant in infants and OMV vaccines were deemed to be of only limited use against heterologous strains However, the international collaborations and exploratory efforts came to fruition when a serious outbreak of MenB disease appeared in New Zealand in the beginning of the s The solution for this problem was to make an OMV vaccine based on that particular circulating strain During the situation in New Zealand it was declared unethical to perform a placebo controlled trial, so after initial safety and immunogenicity studies, the vaccine was offered in a three dose schedule to all million inhabitants less than 20 years of age (later four doses for infants) Effectiveness estimates of for all age groups over a two year observation period were found retrospectively because the staggered roll out of the vaccine in the population resulted in vaccinated and un vaccinated cohorts existing at the same time In the search for a more universal vaccine with broad strain coverage, a number of approaches have been explored; from multi valented PorA based OMV vaccines to single cross reactive antigens as lipopolysaccharides LPS and various minor outer membrane proteins that were assumed to be under less immunological pressure than PorA
The irst substantial breakthrough occurred in 2000 by sequencing the whole genome of a N meningitidis strain and using the in silico mining approach named Reverse Vaccinology The vaccine developed according to these principles was ready 13 years later for licensure and global use under the name CMenB Bexsero , Novartis later GSK The active principle of this vaccine consists of three recombinant proteins factor H binding protein fHbp neisserial heparin binding antigen NHBA and neisserial adhesin A NadA in combination with an OMV component with the PorA porine P The latter is in fact the same vaccine component that was used for controlling the outbreak in New Zealand during the nation wide campaign from 2004 to 2008, mentioned above.
In parallel a more traditional approach consisting The irst universal MenB vaccine on the market in EU was named CMenB with the commercial name Bexsero , from Novartis In another MenB vaccine was licensed in USA called Trumenba rLP P izer http www fda. gov BiologicsBloodVaccines Vaccines ApprovedProducts ucm421020.htm). Thus, the vision of vaccinating against all major disease causing serogroups of meningococci is now a possibility Development of these more universal MenB vaccines required more than 20 years of research, and they represent a solid breakthrough for the prevention of MenB disease globally These vaccines are also the irst protein based bacterial vaccines that are not dependent on toxin neutralization as a key preventive principle. This historical use and integration of knowledge in the ield of vaccinology will also prove important for development of other vaccines in the years to come. Learning points that will be particularly useful, also in more general settings, include selection of strain panels and evaluation of strain coverage for a particular vaccine formulation. Challenges of making the selected vaccine candidates suf iciently immunogenic and cross reactive can pro it from the developmental experience for CMenB and rLP
In addition to the scienti ic issues MenB development and the initial attempts to implement the vaccine in national vaccination programs, also illustrated limitations with the current models for cost effectiveness and thus dif iculties for decision makers to appreciate the true value of vaccines against rare but very serious infectious diseases However from September Bexsero was introduced in the UK childhood immunization program http www meningitis org menb vaccine; http www iercevaccines com story gsk inally seals uk bexsero deal dose ) [88].
It will take at least two to ive years until we know the full clinical impact and value of these new meningococcal vaccines in various epidemiological situations Issues to be studied more carefully are duration of protection in various age groups, mucosal immunity and herd protection. Of particular note, a substantial difference in immunogenicity has been observed with recombinant fHbp versus the experimental formulations of native OMV vaccines where fHbp has been included as over expressed vaccine antigen NOMV OE fHbp with times the ordinary level found in wild type strains The total amount of fHbp in the two formulations can be more than times different and the NOMV formulation induces better anti fHbp immunity than the recombinant vaccine Since fHbp is a membrane attached lipoprotein the NOMV must be manufactured without using the standard detergent extraction established for manufacture of ordinary OMV vaccines Instead the vaccine can be made tolerable for humans with genetic manipulation of LPS (lpx mutants Preclinical studies with NOMV vaccines have shown higher protective titres and broader immune responses, resulting in better capacity to kill strains with fHbp variants that are substantially different from the vaccine antigen selected for the vaccine These observations served as inspiration for further studies of the OMV concept and use of NOMV as a platform for various other antigens This approach might also well provide bene its in the ight against diseases that are in need for better performing vaccines like Thus, in the current situation there are strong indications for continued development and use of the OMV concept in various ways for modern biotechnology and vaccinology, in the decades to come (Figure 2 ).
Improving vaccination for all people
A general Symposium was dedicated to review recent strategies for the sustainable development of vaccines. Dr. Pagliusi, Executive
Secretary of Developing Countries Vaccine Manufacturers Network DCVMN Switzerland explained how DCVMN stands
for improving vaccination to all people: The common mission of all DCVMN members is to protect people against known and emerging infectious diseases, by improving the availability of high quality vaccines globally As an international non governmental non partisan not for pro it public health driven alliance of vaccine manufacturers, research and policy organizations from all over the world, it operates based on principles of sharing knowledge for international scienti ic technical and economic cooperation, guided by common values of equity, responsibility, accountability, transparency and respect. In addition to supplying vaccines for national public immunization programs, the manufacturers have contributed signi icantly to major global health initiatives such as polio eradication, tetanus elimination, measles and rubella elimination, and to supply vaccines such as yellow fever, typhoid fever, meningitis A, Japanese encephalitis, and Hepatitis E vaccines, diseases predominantly relevant on a regional basis.
Developing countries' economies include all countries that
By sharing the common goals of increasing and maintaining the number of vaccines available for international procurement, particularly for GAVI eligible countries while reducing the time to obtaining WHO prequali ication PQ and securing sustainable vaccines supply the Network has launched four initiatives to support manufacturers, as follows: 1) review the design and layout of manufacturing facilities and systems as to ful ill global GMP expectations; 2) Training workshops, to update professionals on recent Good Practices in may areas GXP and PQ requirements 3) create a forum for industry to discuss regulatory challenges with experts; 4) to create a database of expert vaccine consultants for corporate organizations to advance speci ic projects needs
The new initiatives are expected to have an impact on upgrading facilities for priority vaccines, provide consistent information to industry professionals from developing countries on GMP quality management systems and pre quali ication serving as harmonization efforts unlocking new regulatory approaches to improve access to vaccines to bene it people in developing countries, and facilitate access to reliable consulting expertise for members to advance with clinical development, regulatory dossiers partnerships and investments DCVMN has focused efforts in trying to engage members and partners in contributing to the global initiatives.
Notably the demand and supply for the in pentavalent vaccines in developing countries has grown 10 fold in the last years from to million doses procured by UNICEF due to availability from over manufacturers and all GAVI countries have introduced this vaccine today as compared to countries in The goal is that the same pattern proves true for rotavirus, pneumococcal and HPV vaccines, among others, when more manufacturers can make them available.
Vaccines have proven to be an effective strategy in controlling, eliminating and eradicating infectious diseases, as a result of close cooperation and partnerships.
Still much remains to be achieved, as while the global coverage of essential traditional vaccines such as DTP, hepatitis B measles and polio averaged global coverage in the new vaccines such as pneumococcal and rotavirus vaccines is of and respectively and HPV and other vaccines even less. The needs are huge as populations in developing countries continue to grow and so we need strong manufacturers to take up this challenge and scale up the supply of affordable vaccines to control and prevent the spread of infectious diseases globally.
DCVMN has focused efforts in trying to engage members and partners in contributing to the global initiatives. 
